Clinical trials: Subjects With Type 2 Diabetes Mellitus.
NAFLD, Diabetes Mellitus, Type 2
Study of ISIS 703802 in Participants With Hypertriglyceridemia, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver Disease
This is a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the safety, including tolerability, of ISIS 703802 and to assess the efficacy of different doses and dosing regimens of ISIS…
- Conditions
- NAFLD, Diabetes Mellitus, Type 2, Hypertriglyceridemia, Fatty Liver, Nonalcoholic
- Trial name
- NCT03371355
- Testing
- ISIS 703802 40 mg, ISIS 703802 80 mg, ISIS 703802 20 mg
- Where
- 42 sites in United States, Canada
- Volunteers
- 105 people
- Sponsor
- Akcea Therapeutics
Type II Diabetes Mellitus
Efficacy and Safety of GL0034 in Overweight or Obese Adults With Type II Diabetes Mellitus
This is a phase II, randomized, double-blind, placebo-controlled study to evaluate the efficacy and tolerability of GL0034 among type II diabetes mellitus subjects who are obese or overweight with weight-related comorbidities.
- Trial name
- NCT07282743
- Testing
- GL0034 Dose Level 1, GL0034 Dose Level 2, GL0034 Dose Level 3
- Where
- 21 sites in United States, India
- Volunteers
- 285 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Diabetes Mellitus, Type 2
Rosiglitazone on Microalbuminuria in Type 2 Diabetics
Following a 4-week single-blind placebo run-in period, eligible subjects were randomized in a 1:1 ratio to receive 32 weeks of double-blind study medication: Rosiglitazone (starting dose 4mg od) or Glyburide (starting dose 5mg…
- Trial name
- NCT00500955
- Testing
- Rosiglitazone
- Where
- 113 sites in United States, Austria and 9 more
- Volunteers
- 336 people
- Sponsor
- GlaxoSmithKline
Type 2 Diabetes Mellitus
Bioequivalence Study of Fixed Dose Combination of 2.5 mg Saxagliptin/850 mg Metformin Tablet Relative to 2.5 mg Onglyza and 850 mg Glucophage Tablets Co-Administered
To demonstrate bioequivalence of a 2.5 mg saxagliptin/850 mg metformin fixed dose combination (FDC) tablet relative to the 2.5 mg saxagliptin tablet and 850 mg metformin (Glucophage Marketed by Merck-Serono) tablet…
- Trial name
- NCT01068743
- Testing
- saxagliptin, metformin, saxagliptin + metformin (FDC tablet)
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Type 2 Diabetes
Effect of a Basal/Pre-Meal Insulin Strategy (Detemir/Aspart) on Insulin Secretion and Action in Type 2 Diabetes
The optimal insulin therapy in T2DM is controversial and its impact on nonalcoholic fatty liver disease (NAFLD) has not been systematically studied before, and in particular, never when using the new insulin formulations detemir…
- Trial name
- NCT00998335
- Testing
- Long-acting bedtime insulin detemir (Levemir), Insulin detemir and pre-meal insulin aspart.
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Florida
Diabetes Mellitus, Type II
Dual Add-on Therapy in Type 2 Diabetes Poorly Controlled With Metformin Monotherapy
2 weeks screening period, 4 weeks run-in period, 24 weeks double-blind treatment period, to evaluate the Safety and Efficacy of Retagliptin Plus Henagliflozein added to Metformin compared to Retagliptin or Henagliflozein in…
- Trial name
- NCT04667143
- Testing
- Retagliptin, Henagliflozein, metformin XR
- Volunteers
- 760 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Diabetes, Diabetes Mellitus, Type 2
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
This trial is conducted globally. The aim of this trial is to investigate dose-finding of semaglutide administered subcutaneously once daily versus placebo and liraglutide in subjects with type 2 diabetes
- Trial name
- NCT02461589
- Testing
- semaglutide, liraglutide
- Where
- 150 sites in United States, Austria and 8 more
- Volunteers
- 706 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Lantus Versus Levemir Treat-To-Target
Primary objective: To demonstrate the non-inferiority of insulin glargine in comparison to insulin detemir in term of percentage of patients who reach the target of HbA1c < 7% at the end of the treatment period and do not…
- Trial name
- L2T3 (NCT00405418)
- Testing
- Insulin glargine, Insulin Detemir
- Where
- 20 sites in Australia, Brazil and 18 more
- Volunteers
- 973 people
- Sponsor
- Sanofi
Exocrine Pancreatic Insufficiency in Subjects With Diabetes Mellitus Type 2
A Study to Assess the Effect of Creon® on Pancreatic Exocrine Insufficiency in Subjects With Diabetes Mellitus Type 2
maldigestion of dietary macronutrients (pancreas not producing enough enzymes for digestion of fat, sugars and proteins) in diabetes type II
- Trial name
- NCT02009410
- Testing
- Creon
- Where
- 10 sites in Germany, Spain
- Sponsor
- Abbott
Type 2 Diabetes Mellitus
12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
The hypothesis of this Phase 2, 12-week study, is that DS-8500a will improve glycemic control relative to placebo, based on changes in HbA1c, with acceptable safety and tolerability, in patients with Type 2 Diabetes Mellitus…
- Trial name
- NCT02647320
- Testing
- Sitagliptin 100 mg, DS-8500a 25mg
- Where
- 58 sites in United States, Canada
- Volunteers
- 298 people
- Sponsor
- Daiichi Sankyo
Type 2 Diabetes Mellitus
A Trial to Compare Post Prandial Blood Glucose Control of BioChaperone® Combo With Humalog® Mix25 and With Simultaneous Injections of Humalog® and Lantus® in Subjects With Type 2 Diabetes
This is a two-centre, randomised, double-blind, double-dummy, 3-treatment, 3-period cross-over study using a standardised solid meal test in subjects with type 2 diabetes to investigate postprandial glucose control of…
- Trial name
- NCT02915250
- Testing
- BioChaperone® Combo, Humalog® Mix25, Humalog®
- Where
- 2 sites in Germany
- Volunteers
- 36 people
- Sponsor
- Adocia
Diabetes Mellitus, Type 1
An Open-label, Two-center, Randomized, Cross-over Study to Evaluate the Safety and Efficacy of Glycemic Control Using Hybrid-closed Loop vs. Advanced Hybrid Closed-loop in Young Subjects With Type 1 Diabetes
Closed-loop systems are becoming an integral part of diabetes management. These systems were uniformly proven to improve glycemic control, reduce hyperglycemia and hypoglycemia while modestly reducing HbA1c levels and improving…
- Trial name
- NCT04269668
- Testing
- Medtronic Minimed 670G 3.0 HCL, Medtronic Minimed 670G 4.0 AHCL
- Where
- 2 sites in Germany, Israel
- Volunteers
- 28 people
- Sponsor
- Rabin Medical Center
Type 2 Diabetes Mellitus
Lipid, Glycemic, and Insulin Responses to Meals Rich in Different Fatty Acids
A meal rich in very-long chain omega-3 fatty acids or oleic acid may lower postprandial insulin levels in comparison to a meal rich in linoleic acid or palmitic acid.
- Trial name
- NCT00479791
- Testing
- Test meals rich in different fatty acids
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Texas Southwestern Medical Center
Obesity, Type 2 Diabetes
Epigenetic Effects of a Single Bout of Exercise on Cardiovascular Risk Factors and the Metabolome
The purpose of this study is to determine the ability of acute exercise to regulate fat metabolism in muscle of overweight and obese people compared to lean people.
- Conditions
- Obesity, Type 2 Diabetes, Cardiovascular Diseases, Acute Exercise
- Trial name
- NCT05034380
- Testing
- Acute exercise
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- East Carolina University
Diabetes Mellitus, Type 2
Safety and Efficacy Study of Albiglutide in Type 2 Diabetes
The purpose of this study is to determine whether albiglutide is effective in the treament of patients with type 2 diabetes.
- Trial name
- NCT00849017
- Testing
- albiglutide, albiglutide uptitration
- Where
- 262 sites in United States, Mexico and 1 more
- Volunteers
- 309 people
- Sponsor
- GlaxoSmithKline
Type 2 Diabetes
An 18 Week Efficacy and Safety Study of Saxagliptin and Metformin XR Combination in Subjects With Type 2 Diabetes
The purpose of this study is to compare reduction in A1C for subjects taking Saxagliptin and Metformin XR vs. uptitrated Metformin XR.
- Trial name
- SCORE (NCT00960076)
- Testing
- Saxagliptin, Metformin XR
- Where
- 35 sites in United States, Colombia and 3 more
- Volunteers
- 282 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of JNJ-28431754 in Patients With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the safety, tolerability, pharmacodynamic effects and pharmacokinetic characteristics of JNJ-28431754 after multiple dosing in patients with Type 2 Diabetes Mellitus who are on a stable…
- Trial name
- NCT01177163
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Type 2 Diabetes Mellitus
A Drug Interaction Study Between Simvastatin and GSK376501
This study is a 3-period crossover drug interaction study between GSK376501 and simvastatin in healthy adult subjects. This study will examine if repeat doses of GSK376501 affects the pharmacokinetics of simvastatin and if repeat…
- Trial name
- NCT00605449
- Testing
- GSK376501
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Diabetes, Diabetes Mellitus, Type 2
Observational Study on Effectiveness and Safety of Liraglutide in Subjects With Type 2 Diabetes
The study is conducted in Europe. The aim of this observational study is to assess glycaemic control while using liraglutide under normal clinical practice conditions in Belgium.
- Trial name
- ROOTS (NCT01288326)
- Testing
- liraglutide
- Where
- Belgium
- Volunteers
- 254 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus (T2DM)
A Comparison Study of the Bioavailability of a Capsule Formulation of LGD-6972 to an Oral Solution Formulation
The purpose of this study is to compare relative oral bioavailability of a capsule formulation of LGD-6972 to a solution formulation of LGD-6972.
- Trial name
- NCT02672839
- Testing
- LGD-6972 Solution, LGD-6972 Capsules
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Ligand Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.